Background: Platinum-based chemotherapy had been the standard-of-care for the longest time for NSCLC that did not harbor sensitizing EGFR or ALK mutations. Pembrolizumab a fully humanized monoclonal IgG antibody against programmed death-1 (PD-1) showed good activity in patients with NSCLC without sensitizing mutations especially in those that had >50% e…
Keep reading with a 7-day free trial
Subscribe to Hematology Oncology Snippets to keep reading this post and get 7 days of free access to the full post archives.